Our COVID-19 solutions key facts...

Using our science, technology, portfolio and resources to support development of products for prevention and treatment of COVID-19 and the overall global response.

11 June 2020, Update 4

...our science and technology

Our primary aim is to develop multiple adjuvanted COVID-19 vaccines, and we plan to produce 1 billion vaccine adjuvant doses in 2021. So we are:

• Partnering with multiple companies and research groups across the world, including China, North America and EU
• Combining our expertise and scale with Sanofi to develop an adjuvanted vaccine and expect to enter clinical trials in second half 2020

Committed to affordable pricing
We do not expect to profit from our portfolio of collaborations for COVID-19 adjuvanted vaccines. Any short-term profit that may be generated will be invested in support of coronavirus related research and long-term pandemic preparedness

Collaborating with Vir Biotechnology to identify and accelerate new anti-viral antibodies which could be used as therapeutic or preventative options to fight this and future outbreaks

As part of the COVID-19 Therapeutic Accelerator (established by the Bill and Melinda Gates Foundation and Wellcome) we aim to fast track drug repurposing and screening

What is an adjuvant?
An adjuvant can be added to a vaccine to boost the body’s immune response, which means less vaccine is needed for the same result. This is particularly important in a pandemic as more vaccine doses can be available to protect people around the world

Reviewing our marketed medicines and pipeline to determine if any have potential activity against COVID-19 or to treat secondary complications
• Started a clinical trial to assess whether a monoclonal antibody in development can help treat patients who are affected by severe pulmonary COVID-19 related disease

Developing a rapid COVID-19 test that uses patented technology and is reliable, fully disposable and easy-to-use at home

...our existing products

Ensuring continuous supply of our medicines, vaccines and consumer healthcare products
• Running 24/7 working in many manufacturing sites
• Over 20,000 employees working in our manufacturing sites and R&D labs around the world

Increasing production of our high demand products (e.g. multi-vitamins, respiratory medicines and antibiotics) and have so far donated more than 660,000 GSK products to more than 26 countries in Asia, Americas and EU

...our capabilities and expert facilities

Setting up specialised laboratory space to help support national diagnostic testing in the UK, partnering with AstraZeneca and University of Cambridge to introduce automated testing capacity to supplement national centres and in Belgium, conducting large-scale testing at our facility in Rixensart

Providing free curriculum linked STEM resources online in the UK and US, supporting teachers and parents whilst students are at home

...supporting frontline health workers

$10 million to WHO and the UN Foundation’s COVID-19 Solidarity Response Fund to prevent, detect, and manage the pandemic in support of frontline health workers

Over £11.4m in 44 countries donated to local charities and communities including £3m fund from ViV to provide critical financial resources for research projects and community-based grants focused on people living with HIV

Employee donations to support national front-line health worker charities which are matched by GSK e.g. UK NHS Charities Together, US Direct Relief, Italy National Crisis Fund

Donating lab equipment, instruments, and scientific kits to support government testing and over 700,000 PPE units to protect frontline health workers in 32 countries

Employee volunteering with over 260 scientists volunteering across EU, US and SA including diagnostic testing and GSK HCPs volunteering on the frontline